3/3
12:16 pm
ntra
Natera (NTRA) had its price target lowered by Morgan Stanley from $265.00 to $250.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NTRA) had its price target lowered by Morgan Stanley from $265.00 to $250.00. They now have an "overweight" rating on the stock.
2/28
10:31 am
ntra
Natera Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Natera Q4 Earnings Call Highlights [Yahoo! Finance]
2/27
04:26 pm
ntra
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
2/27
01:11 pm
ntra
Natera (NTRA) had its price target raised by Wells Fargo & Company from $205.00 to $215.00. They now have an "equal weight" rating on the stock.
Medium
Report
Natera (NTRA) had its price target raised by Wells Fargo & Company from $205.00 to $215.00. They now have an "equal weight" rating on the stock.
2/27
10:05 am
ntra
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
Low
Report
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
2/27
08:02 am
ntra
Natera (NTRA) had its price target raised by Robert W. Baird from $239.00 to $257.00. They now have an "outperform" rating on the stock.
Medium
Report
Natera (NTRA) had its price target raised by Robert W. Baird from $239.00 to $257.00. They now have an "outperform" rating on the stock.
2/27
12:42 am
ntra
Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... [Yahoo! Finance]
Medium
Report
Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... [Yahoo! Finance]
2/27
12:00 am
ntra
Natera, Inc. (NTRA) Announces Results From the SINERGY Trial [Yahoo! Finance]
Medium
Report
Natera, Inc. (NTRA) Announces Results From the SINERGY Trial [Yahoo! Finance]
2/26
04:05 pm
ntra
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
2/24
06:00 am
ntra
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
Low
Report
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
2/17
01:31 pm
ntra
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update [Seeking Alpha]
Low
Report
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update [Seeking Alpha]
2/17
09:00 am
ntra
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
Medium
Report
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
2/12
09:24 pm
ntra
Allspring Growth Fund Q4 2025 Fund Performers And Detractors [Seeking Alpha]
Low
Report
Allspring Growth Fund Q4 2025 Fund Performers And Detractors [Seeking Alpha]
2/6
06:00 am
ntra
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
Low
Report
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
2/3
10:02 am
ntra
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards [Seeking Alpha]
Low
Report
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards [Seeking Alpha]
2/2
06:00 am
ntra
Natera Submits Signatera™ CDx PMA to FDA
Low
Report
Natera Submits Signatera™ CDx PMA to FDA
1/31
07:19 am
ntra
A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
Low
Report
A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
1/28
08:00 am
ntra
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
Low
Report
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
1/26
06:00 am
ntra
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
Low
Report
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
1/21
06:00 am
ntra
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
Medium
Report
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
1/20
06:00 am
ntra
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
Medium
Report
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
1/13
08:00 am
ntra
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
Low
Report
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
1/12
10:00 am
ntra
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
Low
Report
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
1/12
07:17 am
ntra
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Low
Report
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
1/11
10:48 pm
ntra
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
Medium
Report
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth